

		Recommendation	Description
Dimension	Health impact	Promote collection of robust epidemiological data	<ul style="list-style-type: none"> <li>← Collect robust global burden and AMR data for pathogens where this is absent or incomplete</li> <li>← Pool resources and co-ordinate study methodologies where possible for groups of pathogens to enable multi-pathogen data collection (eg hospital acquired infections)</li> </ul>
		Model evolution of AMR threat and potential health impact of interventions	<ul style="list-style-type: none"> <li>← Build a single model / consortium of modellers for each pathogen to project the evolution of AMR threat over time and the direct health impact of proposed interventions</li> <li>← Collect more AMR-specific data such as resistance rates, antibiotic usage and impact of vaccines on AMR</li> </ul>
	R&D	Target investment to new R&D platforms relevant to AMR pathogens	<ul style="list-style-type: none"> <li>← Assess the potential of new platforms and technologies specifically in their ability to support R&amp;D for AMR pathogens</li> <li>← Target investment towards platforms that have the potential to accelerate development and improve probability of success of candidate vaccines for AMR pathogens</li> </ul>
		Collaborate for regulatory innovation	<ul style="list-style-type: none"> <li>← Engage with regulators to explore inclusion of AMR-related end points and RWE in vaccine trials</li> <li>← Convene regular meetings between industry and regulators</li> </ul>
	Uptake	Utilise market shaping intervention	<ul style="list-style-type: none"> <li>← Encourage Gavi to deepen its focus on AMR and signal potential support for vaccines in earlier stages of development</li> </ul>
		Develop the health economic case for vaccinations	<ul style="list-style-type: none"> <li>← Use global burden data and health economic impact models to align policy and payer support towards the utility of vaccines in reducing the burden of AMR infections</li> </ul>